Session Type: Abstract Session
Session Time: 4:30PM-6:00PM
Background/Purpose: The presentation of new-onset giant cell arteritis (GCA) is highly variable. It is vital to make a secure diagnosis to minimise the risk for visual loss, while excluding the mimicking conditions to avoid unnecessary glucocorticoid exposure. Although imaging tests (e.g., ultrasonography) are increasingly used in case of suspected GCA, the assessment of the clinical probability based on symptoms, signs and lab findings remains crucial. To standardize the estimation of clinical probability, the Southend pre-test probability score (SPTPS) has been recently developed. The SPTPS stratifies patients into low-risk, intermediate-risk and high-risk categories1,2. Retrospective studies from many centres3-6 have externally validated this SPTPS. The current study aimed to validate the SPTPS in a multicentre, prospective study.
Methods: This prospective, multicentre, observational study includes consecutive patients with suspected new-onset GCA recruited at 7 European centres participating in the HAS GCA study. SPTPS was calculated, and patients were stratified into the three risk categories: low-risk < 9, intermediate-risk 9-12 and high-risk >12. All patients underwent vascular ultrasonography (bilateral temporal arteries; common, parietal, frontal branches and axillary arteries). Vascular ultrasonography was considered positive for GCA when the intimal medial thickness is >0.42mm in common temporal, >0.29mm in Parietal, >0.34mm in frontal and >1.0mm in axillary arteries. Additional tests such as temporal artery biopsy, FDG-PET/CT, or CTA were performed at the treating physician’s discretion. The final diagnosis was confirmed after 6 months of follow up.
Results: A total of 226 patients were included in the study. A diagnosis of GCA was confirmed in 83 (36.73%) patients. SPTPS was low-risk in 66 (29.2%) patients, intermediate-risk in71 (31.4%) patients and high-risk in 89 (39.4%) patients (Image). The number of patients with GCA among patients in distinct risk categories was 0 (0%) in low-risk patients, 17 (20.5%) in intermediate-risk patients and 66 (79.5%) in high-risk patients. Among the three risk categories, high diagnostic accuracy was observed for ultrasonography (table).
Conclusion: The SPTPS is a useful tool for assessing the clinical probability of GCA among patients with suspected new-onset GCA. A combination of the SPTPS and vascular ultrasonography accurately discriminated between patients with and without GCA in our prospective, multicentre study.
1. Laskou F, et al. Clin Exp Rheumatol. 2019 Feb 15
2. Sebastian A, et al. RMD Open. 2020;6(3)
3. Melville et al. Rheum Adv in Practice, Volume 6, Issue 1, 2022, rkab102
4. Oshinsky et al. Arthritis Rheumatol. 2021; 73 (suppl 10)
5. Mathake et al. Arthritis Rheumatol. 2021; 73 (suppl 10)
6. Fernández-Fernández et al. RMD Open 2022 Apr;8(1):e002120
To cite this abstract in AMA style:Sebastian A, tomelleri a, MACCHIONI P, Klinowski G, Salvarani C, Kayani A, Tariq M, Prieto-Peña D, Conticini E, Khurshid M, Inness S, Jackson J, van der Geest K, Dasgupta B. Probability-based Diagnostic Algorithm in Suspected Giant Cell Arteritis: A Prospective, Multicentre Validity Data from HAS GCA Study [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/probability-based-diagnostic-algorithm-in-suspected-giant-cell-arteritis-a-prospective-multicentre-validity-data-from-has-gca-study/. Accessed .
« Back to ACR Convergence 2022
ACR Meeting Abstracts - https://acrabstracts.org/abstract/probability-based-diagnostic-algorithm-in-suspected-giant-cell-arteritis-a-prospective-multicentre-validity-data-from-has-gca-study/